MEI Pharma Inc MEIP:NASDAQ

RT Quote | NASDAQ | USD
Last | 11/29/21 EST
2.45quote price arrow down-0.16 (-6.13%)
Volume
925,981
52 week range
2.40 - 4.58
Loading...
  • Open2.68
  • Day High2.70
  • Day Low2.45
  • Prev Close2.45
  • 52 Week High4.58
  • 52 Week High Date02/08/21
  • 52 Week Low2.40
  • 52 Week Low Date07/27/21

Key Stats

  • Market Cap276.07M
  • Shares Out112.68M
  • 10 Day Average Volume0.48M
  • Dividend-
  • Dividend Yield-
  • Beta1.48
  • YTD % Change-7.2

KEY STATS

  • Open2.68
  • Day High2.70
  • Day Low2.45
  • Prev Close2.45
  • 52 Week High4.58
  • 52 Week High Date02/08/21
  • 52 Week Low2.40
  • 52 Week Low Date07/27/21
  • Market Cap276.07M
  • Shares Out112.68M
  • 10 Day Average Volume0.48M
  • Dividend-
  • Dividend Yield-
  • Beta1.48
  • YTD % Change-7.2

RATIOS/PROFITABILITY

  • EPS (TTM)-0.54
  • P/E (TTM)-4.57
  • Fwd P/E (NTM)-3.78
  • EBITDA (TTM)-44.004M
  • ROE (TTM)-106.04%
  • Revenue (TTM)40.92M
  • Gross Margin (TTM)95.38%
  • Net Margin (TTM)-154.77%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date02/02/2022
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On MEI Pharma Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
MEI Pharma, Inc. is a late-stage pharmaceutical company. The Company is focused on development and commercialization of novel cancer therapies. The Company's portfolio of clinical drug candidates includes Zandelisib (f/k/a ME-401), Voruciclib, ME-344, and Pracinostat. Its Zandelisib is an oral phosphatidylinositol 3-kinase (PI3K) delta inhibitor for the treatment of B-cell malignancies. The Company is conducting Phase II study evaluating zandelisib as a monotherapy in...
Christine White M.D.
Non-Executive Chairman
Daniel Gold Ph.D.
Chief Executive Officer
David Urso J.D.
Chief Operating Officer
Brian Drazba CPA
Chief Financial Officer
Address
11455 EL CAMINO REAL, SUITE 250
San Diego, CA
92130
United States

Top Peers

SYMBOLLASTCHG%CHG
AQST
Aquestive Therapeutics Inc
6.08-0.29-4.55%
PLXP
PLx Pharma Inc
9.34-0.93-9.06%
HROW
Harrow Health Inc
9.99-0.28-2.73%
CDXC
Chromadex Corp
4.75-0.16-3.26%
RLMD
Relmada Therapeutics Inc
18.15-0.68-3.61%